Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Clinical results supporting efficacy of newer generation COX-2 inhibitor presented at ASCPT

March 17, 2000

Sigma-Tau prepares improved atypical antipsychotic agents

March 17, 2000

SB continues to search for novel anticonvulsants

March 17, 2000

Shire and D-Pharm reach agreement for development of DP-VPA for epilepsy

March 17, 2000

Antiepileptic agents under study at Arzneimittelwerk Dresden

March 16, 2000

Ampakine-like compounds for psychiatric and neurological disorders

March 16, 2000

Otsuka prepares new orally active analgesic agents

March 16, 2000

Anesta renegotiates U.S. marketing rights for Actiq with Abbott

March 16, 2000

Multiple-dose clinical study of Betabloc as Alzheimer's therapy to begin soon

March 16, 2000

Lilly files NDA for new formulation of Prozac for depression

March 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...